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Abstract 
Being a member of the serotonin receptor family, 5-
HT4 receptor ties up the neurotransmitter-serotonin 
(5-hydroxytryptamine/ 5-HT) in the central nervous 
system (CNS) of mammals. Commonly 5-HT4 
receptors (5-HTR4) are G-protein-coupled receptors 
(GPCRs), in which the G proteins cause the 
induction of adenylate cyclase, subsequently leading 
to cyclic adenosine monophosphate (cAMP) and 
protein kinase A (PKA) activations. These receptors 
are commonly expressed in gastrointestinal, 
cardiovascular, nervous, and urinary systems, as 
well as the adrenal cortex (Tack et al., 2012).  
In this review article, the genetic, cellular, and 
biochemical knowledge of 5-HT4 receptors is 
deliberated. Besides the emphasis on receptor-ligand 
interaction with therapeutics, the implication of 
these receptors in several health 
disturbances/diseases is considered on the basis of 
available literature. 
Keywords 
5-hydroxytryptamine receptor 4, Serotonin (5-HT), 
Central Nervous System (CNS), Alzheimer's 
Disease, Inflammatory Bowel Disease (IBD), 
Obesity. 
Identity 
Other names 
5-HT4, 5-HT4R 
HGNC (Hugo): HTR4 
Location: 5q32 
Local order: Shown in Chromosome 5 - 
NC_000005.10 Reference GRCh38.p13 Primary 
Assembly. Cytogenetic Location of 5-HTR: 5q32, 
which is the long (q) arm of chromosome 5 at a 
position 32 (UCSC Genome Browser on Human 
Dec. 2013 (GRCh38/hg38) Assembly) 
DNA/RNA 
Note 
The 5-HTR4 gene is 172,607 bp long (according to 
UCSC, GRCh38/hg38), located on the minus (-) 
strand and spans 12 exons (NCBI Homo sapiens 
Annotation Release 109). 
Transcription 
The gene has 13 transcripts (Table 1) 
Name Transcript ID bp 
Protein 
(aa) 
Biotype 
HTR4-
201 
ENST00000360693.7 3082 428 
Protein 
coding 
HTR4-
202 
ENST00000362016.6 2979 428 
Protein 
coding 
HTR4-
203 
ENST00000377888.7 2962 388 
Protein 
coding 
HTR4-
209 
ENST00000521530.5 1323 387 
Protein 
coding 
HTR4-
210 
ENST00000521735.5 1242 378 
Protein 
coding 
HTR4-
207 
ENST00000520514.5 1236 411 
Protein 
coding 
HTR4-
213 
ENST00000631296.1 1224 388 
Protein 
coding 
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HTR4-
204 
ENST00000517929.5 1201 360 
Protein 
coding 
HTR4-
206 
ENST00000520086.1 2272 87 
Protein 
coding 
HTR4-
211 
ENST00000522588.5 1326 378 
Nonsense 
mediated 
decay 
HTR4-
212 
ENST00000524063.3 2274 371 
Nonsense 
mediated 
decay 
HTR4-
205 
ENST00000519495.1 869 
No 
protein 
Processed 
transcript 
HTR4-
208 
ENST00000521124.5 1221 
No 
protein 
Retained 
intron 
Table 1. Transcripts of the human 5-HTR4 gene 
(Ensemble, GRCh38.p12). 
Protein 
The product of HTR4 gene (5q32) is 5-HT4 receptor 
(Ohtsuki et al., 2002), weight as 43.761 Dalton with 
a length of 388 amino acids (Blondel et al., 1997; 
Claeysen et al., 1997; Van den Wyngaert et al., 
1997). The protein has 9 known isoforms produced 
by alternative splicing, but the potential isoforms 
seem to exist  (https://www.uniprot.org/ 
uniprot/Q13639). Isoform 5-HT4(B) (Q13639-1) 
was considered as canonical sequence and provided 
in Figure 1. The translated glycoprotein is a member 
of the serotonin receptor family which are induced in 
response to the presence of serotonin via G-protein 
coupling process. In general, the 5-HT4 receptor is a 
glycosylated transmembrane protein expressed in 
both CNS and peripheric nervous system (PNS) that 
acts as a modulator in the release of various 
neurotransmitters (NCBI). It expressed in various 
tissues/cells such as the brain, esophagus, ileum, 
colon, bladder, heart, and adrenocortical cells. In the 
brain, they are particularly expressed in the 
hypothalamus, nucleus accumbens, amygdala, 
Calleja islands, olfactory tubercle, fundus striatum, 
ventral pallidum, septum, hippocampus, and basal 
ganglia including substantia nigra (Bockaert et al., 
2008). 
 
Figure 1.  A canonical protein sequence (388 amino acids) 
of the human 5-HT4 receptor (PDB ID 5EM9.B) (Data was 
taken from the https://www.rcsb.org/pdb/protein/Q13639) 
Expression 
5-HTR4 is expressed in different human 
tissues/organs but mostly in gastrointestinal tract, 
brain, and muscles in descending order. Please see 
The Human Protein Atlas (http://www. 
proteinatlas.org) 
Function 
5-hydroxytryptamine (5-HT or serotonin) is a crucial 
neurotransmitter of CNS with highly conserved 
monoamine structure (Hodge et al., 2013). It plays a 
role in different physiological events of CNS and 
PNS by interacting with more than one receptor 
subtype (Cichon et al., 1998). These countless 
functions are actualized by seven 5-HT subtype 
receptors (Kroeze et al., 2002; Hodge et al., 2013).  
The 5-HTR4 is a G-protein-coupled receptor that 
arouses adenylate cyclase as a primary mode of 
signal transduction. By the arousal of adenylate 
cyclase, the concentration of cAMP elevates (Lalut 
vd., 2017). However, 5-HTR4 refers to both G 
protein-dependent and G protein-independent 
pathways (Figure 2a-b). The main G protein 
introduced by 5-HTR4 signaling is the Gs (shown in 
Figure 2a) that leads to the activation of the cAMP/ 
PKA pathway (Barthet et al., 2005). The G-protein 
independent non-canonical pathway activates Src 
(shown in Figure 2b) and subsequently ERK kinases, 
causing pERK1/ 2 phosphorylation (Barthet et al., 
2007).  
This receptor was first described in primary cultures 
of mouse embryonic colliculus neurons based on 5-
HT-induced cAMP production (Dumuis et al., 
1988). It plays potential roles in the physiology of 
cardiovascular, urinary, and endocrine systems. It is 
also implicated in the pathophysiology of diseases 
occurring in adrenal glands as well as urinary and 
gastrointestinal systems (Ford and Clarke., 1994). 5-
HTR4s are responsive in the events occurring in 
adrenal glands, colon, cortex (Monferini et al.,1993), 
and atrial appendages (Kaumann et al., 1990, 1991; 
Turconi et al., 1991; Quadid et al., 1992) of human 
tissues by encouraging cAMPs. In turn, cAMP 
inductions lead to steroid secretion in adrenal glands 
(Lefebvre et al., 1992) and circular muscle 
contraction in the colon (Tam et al.,1992).  
 Therapeutic agents interacting with 5-HTR4   
Advances in research on 5-HT set forward the 
development of therapeutics selectively interacting 
with 5-HT receptors. In the present day, these 
ligands mainly divided into 5 categories/classes. 
They are indoles including 5-HT analogs, indole 
carboxylates, and indole carboxamides, benzamides, 
benzoates, aryl ketones, and benzimidazoles 
(Bockaert et al., 2004).  
First-class 5-HTR4 agonists include substituted 
tryptamines or 5-HT agonists next to the substituted 
triple-carbazimidamides. 5-MeOtryptamine is an 
interesting vehicle due to the lack of its affinity to 5-
HTR3 (Craig et al., 1990). The indole 
carbazimidamide derivative, HTF 919 (Tegaserod), 
has been found to be a potent partial agonist with 
high affinity to 5-HTR4. In vivo studies show that 
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Tegaserod enhances gastrointestinal motor activity 
and adjusts impaired motility throughout the 
gastrointestinal tract. (Bockaert et al., 2004). 
Tegaserod is a benzamide derivative which was 
approved by the FDA and other regulatory agencies 
for the treatment of women with inflammatory 
bowel disease (IBD) in which the constipation is 
predominant or functional constipation (Tonini and 
Pace 2006; Shin et al., 2015).  
However, it was later withdrawn from the market 
due to possible cardiovascular side-effects (Chey et 
al., 2008; Thompson 2007).  
Three novel 5-HTR4 agonists (Prucaloprid, 
Naronapride, and Velusetrag) have therapeutic 
potential for patients with IBD.  
These alternative drugs have a higher affinity for 5-
HTR4 compared to Tegaserod (Halland and Talley, 
2013). YKP10811 is a mucosal partial agonist for the 
5-HTR4, induces serotonin release, initiates 
peristaltic reflex, and has a low cardiovascular 
adverse effect. Unlike traditional prokinetic drugs 
such as Tegaserod, YKP10811 exhibits an 
antinociceptive effect on inflammation as well as 
acute stress-associated colonic hypersensitivity, and 
also considered as a candidate drug for IBD (Gilet et 
al., 2014).  
 
Figure 2.  A simplified pathway of G-protein dependent (a) and G-protein independent (b) signaling of 5-HTR4s (Modified from 
Bockaert et al., 2008) 
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Figure 3.  A simplified pathway showing release of 5-HT and it's interaction with 5-HTR4 in neuronal cells. Data were adopted 
and modified from KEGG: Kyoto Encyclopedia of Genes and Genomes (https://www.genome.jp/kegg/) in August 2019 
 
The second class of 5-HTR4 agonists includes first-
generation benzamides carrying '2-methoxy-4-
amino-5-chloro' substitution (Dumuis et al., 1989). 
These benzamides (zacopride, renzapride, and 
metoclopramide) were found to be non-selective and 
always cause antagonistic activity at the 5-HTR3 
(Bockaert et al., 2004).  
The third class of agonists, so-called benzoate 
derivatives were deliberated with the replacement of 
benzamide's amide bond with an ester one, resulting 
in increased affinity for 5-HTR4. The first partial and 
selective drug of this series is ML 10302, which has 
a high affinity for 5-HTR4 and poor affinity for other 
5-HT receptor subtypes including 5-HTR3 (Langlois 
et al., 1994; Bockaert et al., 2004). Moser and 
colleagues (2002) synthesized SL65.0155, a novel 
compound with high affinity for 5-HTR4. Being a 
benzodioxane derivative, it is particularly effective 
for learning and memory (Moser et al., 2002).  
The fourth class is consist of benzimidazoles (BIMU 
8 and BIMU 1), which are potent and effective 5-
HTR4 agonists entering CNS (Dumuis et al., 1991; 
Rizzi et al., 1992). To overcome their metabolic 
variability, aryl ketones were prepared with 5-HTR4 
ester ligands; instead of the ester linkage of the 
antagonist RS 23597, a partial agonist RS 17017 was 
synthesized, which has a similar affinity for 5-HTR4 
(Clark et al., 1994). Increasing the size of the alkyl 
group led to an increase in the activity of the agonists 
RS 67333 and RS 67506 (Eglen et al., 1995). RS 
67333, a selective 5-HTR4 partial agonist, is known 
to easily cross the blood-brain barrier. Systemic 
administration of selective 5-HT4 receptor partial 
agonists, like RS 67333 and RS 17017, enhances 
rodent performance in olfactory relational learning 
(Marchetti et al., 2004), social-spatial memory tests 
(Letty et al., 1997), and also improves delayed 
sample matching in young/ old macaques (Terry et 
al., 1998). RS 67333 has been shown to inhibit β-
amyloid peptide formation in primary cortical 
neurons (Cho and Hu, 2007).  
Interestingly, RS 67333 produces a rapid 
antidepressant effect after only three days of 
administration to rodents (Lucas et al., 2007). A 
more recent study comparing RS67333 with 
antidepressant drug Fluoxetine (FLX) confirmed 
that RS67333 causes anxiolytic-like effects after 
only 7 days in several behavioral tests and that 5-
HTR4 agonists produce faster effects than currently 
used antidepressants (Mendez-David et al., 2014). 
Another interesting agonist is a pyridine 
carboxamide, a cognitive drug (VRX-03011) for 
Alzheimer's disease (Bockaert et al., 2008).  
Fifth class includes indoles such as GR 113808 with 
high affinity for 5-HTR4, and low affinity for 5-
HTR3 (Gale et al., 1994). Further, [3H] GR 113808 
is the first commercially available radioligand for 5-
HTR4 affinity studies (Grossman et al., 1993). SB 
203186 is an indole ester with potent and selective 
5-HTR4 antagonistic properties in various 
physiological assays, but the short half-life limits it's 
in vivo application (Parker et al., 1993).  
In contrast, SB 207266 is a highly potent and 
selective antagonist with a long duration of action 
after oral administration (Gaster et al., 1995). SB 
207266 is a very useful vehicle in CNS studies 
(Wardle et al., 1996; Gaster and King 1997).  
Three selective and high-affinity 5-HTR4 
antagonists (GR 125487, SB 207266, and ML 
10375) have been reported to exhibit reverse 
agonistic activity (Claeysen et al., 2000; Blondel et 
al., 1998).  
Roche Bioscience generated three potent 5-HTR4 
reverse agonists, RO 116-2617, RO 116-0086, and 
RO 116-1148 (Joubert et al., 2002). 5-HTR4 ligands 
that may be of interest in CNS studies are listed in 
Table 2.  
Agonists Antagonists Reverse Antagonists 
5-HT GR 113308 RO 116-2617 
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5-MeOT GF 125487 RO 116-0086 
HTF919 SB 203186 RO 116-1148 
Cisapride LY 353433   
SC 53 116 SB 207 266   
SB 205 149 SB 204070   
Prucalopride RS 23597   
Mosapride ML 10375   
Y-34959 ATBI 221   
ML10302 RS 39606   
LS-65 0155 RS 67532   
RS 67333 RS 100235   
RS 67506 RS 100302   
BUMI 1     
BUMI 8     
Table 2.  5-HTR4 ligands used in CNS studies 
(Adopted from Bockaert et al., 2004). 
Homology 
Pairwise Aligment Scores 
Gene Identity (%) 
Species Symbol Protein DNA 
H.sapiens HTR4     
vs. P.trogladytes HTR4 99,8 99,6 
vs. M.mulatta HTR4 98,6 98,1 
vs. C.lupus HTR4 96,6 93,6 
vs. B.taurus HTR4 94,8 93,7 
vs. M.musculus Htr4 93,3 90,9 
vs. R. norvegicus Htr4 92,7 90,6 
vs. G. gallus HTR4 88,5 82,6 
vs. X. tropicalis LOC100493952 83,4 74,5 
vs. D. rerio LOC556843 75,3 71,9 
vs. D. melanogaster Oa2 47,5 54,3 
Table 3.  Pairwise alignment of 5-HTR4 gene protein 
sequences (in distance from human) (HomoloGene, NCBI). 
Mutations 
Somatic 
A list of 5-HTR4 mutations in cancer can be found 
in COSMIC, the Catalogue Of Somatic Mutations In 
Cancer, https://cancer.sanger.ac.uk/cosmic/gene/ 
analysis?ln=HTR4. According to the Human Protein 
Atlas, HTR4 has been found strongly expressed in 
prostate and endometrial cancers. 
Implicated in 
Animal Experiments 5-HTR4 was initially 
identified in cultured mouse colliculus cells and 
guinea pig brain using a functional cAMP 
stimulation assay (Dumuis et al., 1988). One of the 
oldest functions attributed to 5-HTR4 in rodents is 
related to its role in increasing the release of 
acetylcholine in the frontal cortex (Siniscalchi et al., 
1999) and a stimulating effect on the hippocampus 
to enhance memory and cognition (Bijak et al., 1997; 
Mohler et al., 2007). The absence of this receptor has 
been found to impair stress-induced hypophagia and 
novelty-induced discovery efficiency in mice 
(Compan et al., 2004a). The 5-HTR4 expression is 
also associated with the development of certain 
behavioral characteristics of depression, like 
deletion or pharmacological blockade of 5-HTR4s 
results in increased depressive and anxiety-like 
behaviors in rodents (Carr and Lucki, 2011; Compan 
et al., 2004a; Conductier et al., 2006). Serotonin 
affects cardiac contraction by interacting with 5-
HTR4 expressed in the human and porcine atrium 
and ventricle, interestingly, expressed only in the 
atrium in the rat. 5-HTR4 activation causes cardiac 
spasm as well as tachycardia and arrhythmia 
(Qvigstad et al., 2005). This cardiac effect of 5-
HTR4 is limited to human and porcine atria and are 
not declared in other laboratory animals such as rats, 
guinea pigs, rabbits, and frogs. Moreover, 5-HTR4 
activation triggers the release of acetylcholine in the 
ileum of guinea pig and causes esophageal and 
colonic strictures (Hoyer et al., 2002). 
Inflammatory bowel disease (IBD) 
5-HTR4s which are widely expressed in the human 
intestine can also be expressed in inhibitory nitrergic 
neurons to induce smooth muscle relaxation and 
cholinergic neurons to control muscle contraction 
(Bockaert et al., 2011; Hoffman et al., 2012). In 
addition to their neuronal localization, they are found 
in enterocytes and enteroendocrine cells of the 
intestinal mucosa that regulate fluid, mucus and 5-
HT secretion (Hoffman et al., 2012; Tonini, 2005). 
Accordingly, 5-HTR4s are attractive targets for the 
treatment of IBD. The receptor agonists increase 
motility and accelerate transit from the gut, thereby 
help in the alleviation of IBD and functional 
constipation (Halland and Talley, 2013). More 
selective 5-HTR4 agonists, including Naronapride 
(ATI-7505), Prucaloprid and Velusetrag (TD-5108), 
effectively target this receptor to support the 
intestinal motility. However, the full mechanism of 
action of these compounds is not clearly resolved. 
One possibility is that 5-HTR4 agonists increase 
mobility by stimulating receptors on the enteric 
nerve terminals and increasing neurotransmitter 
release (Hoffman et al., 2012). A single nucleotide 
polymorphism (SNP) (rs201253747) c.* 61T>C in 
HTR4 were identified in diarrhea-IBD patients 
(Wohlfarth et al., 2017). miRNAs can adjust HTR4 
expression, and this regulation can be influenced 
either by the SNP c.*61 T>C or by lessened amounts 
of miR-16 and miR-103 proposing the role HTR4 in 
the pathogenesis of IBD (Wohlfarth et al., 2017). 
Colonic biopsy specimens from patients with 
Crohn's disease also showed greatly increased 
mucosal 5-HTR4 expression (Shajib et al., 2018). 
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Cardiac Disorders 
5-HTR4 is expressed in the atria and ventricles in 
humans; just like other serotonergic receptors, its 
expression level is quite low under physiological 
state but may increase significantly in the case of 
ventricular dysfunction. 5-HTR4 activation is known 
to cause heart spasms, as well as tachycardia and 
arrhythmia (Qvigstad et al., 2005). Even at low 
expression levels, 5-HTR4 increases contraction 
strength (inotropic effect), accelerates early stage of 
muscle relaxation (lusitropic effect) or enhances 
pulse rate (chronotropic effect) (De Maeyer et al., 
2008). Since 5-HT is a neurotransmitter responsible 
for blood pressure regulation, peristaltic movements, 
heart rate, and coagulation system, it acts on 5-HTR4 
in the human heart, producing a positive inotropic 
effect on the stimulation of the atrium (Dorszewska 
et al., 2017). 
Cushing's Syndrome 
5-HTR4 has been shown to be overexpressed in the 
cortex of the adrenal gland in Cushing's syndrome, a 
disease that is caused by cortisone overproduction 
(Cartier et al., 2003). In one study, cortisol secretion 
was encouraged with chorionic gonadotropin, 
luteinizing hormone, and 5-HTR4 stimulating drugs 
in patients with Cushing's syndrome (Lacroix et al., 
1999). Long-term suppression of luteinizing 
hormone secretion by administering leuprolide 
acetate every four weeks led to a complete reversal 
of Cushing's syndrome (Lacroix et al., 1999). The 
administration of 5-HTR4 agonists such as 
metoclopramide, cisapride, and tegaserod stimulated 
aldosterone levels (Zwermann et al., 2009; Lefebvre 
et al., 2002; Cartier et al., 2005). Specific 5-HTR4 
antagonists such as GR 113808 are potent inhibitors 
of basal and/or cisapride-induced aldosterone 
secretion (Lefebvre et al., 2002). 
Asthma 
The 5-HTR4 gene is located in an area previously 
associated with an increased risk of Asthma and 
Atopy (allergic diseases). Previously, 32 genetic 
variants in HTR4 consisting of 22 intronic SNPs, 2 
SNPs in the 3'-untranslated region (exon 7) and 8 
SNPs in the 3'-downstream region were examined 
(Kim et al., 2011). Logistic regression analysis 
demonstrated the relationship between the 2 intronic 
polymorphisms with the risk of Asthma. Two minor 
HTR4 alleles, +142828G>A and +122769G>A, 
appeared at higher frequencies in the Asthma 
patients compared to healthy individuals. Therefore, 
SNP and haplotypes of the HTR4 gene have been 
reported to be associated with the Asthma phenotype 
(Kim et al., 2011). 
Obesity 
Obesity has been associated with chronic elevation 
of brain serotonin levels in humans (Lambert et al., 
1999). Animal studies showed that 5-HTR4 is 
involved in food intake. The genetic or 
pharmacological modifications of the receptor in 
pleasure-associated brain segments modulate food 
intake as well (Haahr et al., 2012). It has been also 
reported that there is a strong positive correlation 
between body mass index (BMI) and 5-HTR4 
concentrations in pleasure circuits (nucleus 
accumbens and ventral pallidum) controlling food 
intake, as well as in the left hippocampal region and 
orbitofrontal cortex. Therefore, stimulation of brain 
5-HTR4s may be considered in the reduction of 
human hedonic overeating (Haahr et al., 2012). The 
direct stimulation of 5-HTR4s in the nucleus 
accumbens reduces the physiological drive to eat and 
increases cocaine- and amphetamine-regulated 
transcript (CART) mRNA levels in fed and food-
deprived mice (Jean et al., 2007). The 5-HTR4 was 
shown to regulate CART mRNA expression through 
cAMP/PKA signaling pathway. This receptor-
mediated upregulation of CART in the nucleus 
accumbens triggers the appetite-suppressant effects 
of ecstasy (Jean et al., 2007). The mechanisms 
underlying feeding disorders in 5-HT4 receptor 
knockout mice are related to a lesser efficacy of 5-
HT (hypothalamus, nucleus accumbens), leptin and 
the cocaine-amphetamine related transcript to reduce 
food intake following stress (Compan et al., 2004b). 
These results show that 5-HTR4 plays an important 
role in nutritional behavior. 
Huntington's Disease 
Post-mortem brain samples of Huntington's disease 
patients revealed a 50% loss of 5-HTR4 in putamens 
(Reynolds et al., 1995). 
Alzheimer's Disease 
Studies focused on neurodegenerative disorders such 
as Alzheimer's disease associated with decreased 
expression of 5-HTR4 in the hippocampus and 
prefrontal cortex (Reynolds et al., 1995). Activation 
of 5-HTR4s stimulates acetylcholine release in the 
prefrontal cortex and hippocampus and improves 
learning and memory in various acquisition and 
memory paradigms (Cachard-Chastel et al., 2008; 
Bockaert et al., 2011). These findings suggest that 5-
HTR4 agonists can be used to improve cholinergic 
function and cognition in Alzheimer's disease. The 
impact of 5-HTR4s on the non-amyloidogenic 
metabolic pathway of the amyloid precursor protein 
by stimulation of α-secretase has been described  
(Lezoualc'h and Robert, 2003; Cachard-Chastel et 
al., 2007). Stimulation of 5-HTR4 triggers soluble 
amyloid precursor protein α (sAPPα) release and 
reduces amyloid-beta (aβ) peptide formation in 
neuronal cell cultures (Maillet et al., 2003; Cho and 
Yu, 2007). A significant loss of 5-HTR4 was 
observed in the hippocampus and frontal cortex of 
patients suffering from Alzheimer's disease. This 
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reduction in certain cerebral concentrations of 5-
HTR4 has demonstrated its effects on cognitive 
learning and memory processes and has been 
recently described as a valuable target against 
Alzheimer's. (Lalut et al., 2017). 5-HTR4 receptor 
agonists are known to improve memory deficits by 
increasing acetylcholine neurotransmission 
(Consolo et al., 1994; Bockaert et al., 2011; Johnson 
et al., 2012). In a transgenic Alzheimer's mouse 
model, stimulation of 5-HTR4 by agonists led to 
cognitive effects resulting in increased learning at 
elevated levels of acetylcholine (Consolo et al., 
1994; Baranger et al., 2017; Bockaert et al., 2011; 
Brodney et al., 2012). In other words, 5-HTR4 
stimulation improves performance in memory tasks 
in rodents, while receptor antagonists cause 
performance deterioration in these tasks. In view of 
all this, 5-HTR4 activation may have beneficial 
effects on Alzheimer's disease, both by preventing 
disease formation and by improving memory 
performance (Rebholz et al., 2018). 
Schizophrenia 
Limited evidence suggests that 5-HTR4 
polymorphisms may be associated with 
susceptibility to Schizophrenia (Suzuki et al., 2003), 
attention deficit, and hyperactivity disorder (Li et al., 
2006). 5-HTR4 plays a role in cognitive function; 
that is assumed to be one of the main disorders of 
Schizophrenia. HTR4 coding regions were examined 
in 96 Japanese Schizophrenia patients. Within the 
coding region, a silent SNP and six intronic SNPs 
were detected and a significant relationship was 
reported between Schizophrenia and haplotype A-T 
(Suzuki et al., 2003). 
Suicidal behavior 
In a study evaluating the role of HTR4 on suicidal 
behavior, significantly high levels of 5-HTR4 and 
cAMP were found in the frontal cortex and caudate 
nucleus of the depressed suicide victims (Rosel et al., 
2004). Another secondary messenger 5-HTR4, 
1,4,5-inositol triphosphate (IP3) were elevated in the 
caudate nucleus and hippocampus, whereas no 
changes were observed in these parameters in the 
amygdala region. The caudate nucleus appears as the 
most affected brain site on account of the significant 
changes in the serotonergic system and thereby is 
important in terms of diagnostic sensitivity (Rosel et 
al., 2004). 
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